STOCK TITAN

[Form 4] Akari Therapeutics Plc Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Akari Therapeutics (AKTX) disclosed a Form 4 showing its Interim CFO acquired 6,277 American Depositary Shares on October 22, 2025, reported as code A at $0.74 per ADS. Following the transaction, 6,277 ADS are beneficially owned with direct ownership.

The filing notes these ADSs represent restricted stock units (RSUs)vest on October 31, 2025. Each ADS represents 2,000 Ordinary Shares of the company.

Akari Therapeutics (AKTX) ha divulgato un modulo 4 che mostra che il suo Interim CFO ha acquistato 6.277 azioni ADR il 22 ottobre 2025, riportate come codice A a $0,74 per ADS. A seguito della transazione, 6.277 ADS sono possedute beneficiariamente con proprietà diretta.

La dichiarazione indica che queste ADS rappresentano unità azionarie vincolate (RSU) che maturano il 31 ottobre 2025. Ogni ADS rappresenta 2.000 azioni ordinarie della società.

Akari Therapeutics (AKTX) reveló un Formulario 4 que muestra que su CFO interino adquirió 6,277 Acciones de American Depositary el 22 de octubre de 2025, reportadas como código A a $0,74 por ADS. Tras la transacción, 6,277 ADS son de propiedad beneficiosa con propiedad directa.

El archivo indica que estas ADS representan unidades de acciones restringidas (RSUs) que vencen el 31 de octubre de 2025. Cada ADS representa 2.000 acciones ordinarias de la empresa.

Akari Therapeutics (AKTX)가 2025년 10월 22일에 6,277 American Depositary Shares를 취득한 임시 CFO의 Form 4를 공개하였으며, 코드 A로 ADS당 $0.74로 보고되었습니다. 거래 후 6,277 ADS직접 소유로 이익 귀속됩니다.

공시는 이들 ADS가 제한 주식단위(RSUs)이며 2025년 10월 31일에 vest됩니다. 각 ADS는 회사의 2,000주 일반주를 나타냅니다.

Akari Therapeutics (AKTX) a divulgué un Form 4 indiquant que son CFO intérimaire a acquis 6 277 Adrs sur le 22 octobre 2025, reporté sous le code A à $0,74 par ADS. À la suite de la transaction, 6 277 ADS sont détenues bénéficiairement avec une propriété directe.

Le dossier précise que ces ADS représentent des unités d’actions restreintes (RSUs) qui viennent à maturité le 31 octobre 2025. Chaque ADS représente 2 000 actions ordinaires de la société.

Akari Therapeutics (AKTX) veröffentlichte Form 4, dass sein Interim-CFO 6.277 American Depositary Shares am 22. Oktober 2025 erworben hat, gemeldet als Code A zu $0,74 pro ADS. Nach der Transaktion sind 6.277 ADS mit direkter Eigentümerschaft vorteilhaft gehalten.

Die Einreichung stellt fest, dass diese ADS Restricted Stock Units (RSUs) sind, die am 31. Oktober 2025 vesten. Jede ADS repräsentiert 2.000 Stammaktien des Unternehmens.

Akari Therapeutics (AKTX) كشفت عن نموذج 4 يبيّن أن مديرها المالي المؤقت اشترى 6,277 سهماً أمريكياً مُصدّراً (ADS) في 22 أكتوبر 2025، مُبلّغ عنها كرمز A بقيمة $0.74 للسهم ADS. بعد الصفقة، أصبحت 6,277 ADS مملوكة بشكل مستفيد بملكية مباشرة.

تشير الإيداع إلى أن هذه هي وحدات أسهم مقيدة (RSUs) التي تكتسب الحقوق في 31 أكتوبر 2025. كل ADS تمثل 2,000 سهماً عاديّاً للشركة.

Positive
  • None.
Negative
  • None.

Akari Therapeutics (AKTX) ha divulgato un modulo 4 che mostra che il suo Interim CFO ha acquistato 6.277 azioni ADR il 22 ottobre 2025, riportate come codice A a $0,74 per ADS. A seguito della transazione, 6.277 ADS sono possedute beneficiariamente con proprietà diretta.

La dichiarazione indica che queste ADS rappresentano unità azionarie vincolate (RSU) che maturano il 31 ottobre 2025. Ogni ADS rappresenta 2.000 azioni ordinarie della società.

Akari Therapeutics (AKTX) reveló un Formulario 4 que muestra que su CFO interino adquirió 6,277 Acciones de American Depositary el 22 de octubre de 2025, reportadas como código A a $0,74 por ADS. Tras la transacción, 6,277 ADS son de propiedad beneficiosa con propiedad directa.

El archivo indica que estas ADS representan unidades de acciones restringidas (RSUs) que vencen el 31 de octubre de 2025. Cada ADS representa 2.000 acciones ordinarias de la empresa.

Akari Therapeutics (AKTX)가 2025년 10월 22일에 6,277 American Depositary Shares를 취득한 임시 CFO의 Form 4를 공개하였으며, 코드 A로 ADS당 $0.74로 보고되었습니다. 거래 후 6,277 ADS직접 소유로 이익 귀속됩니다.

공시는 이들 ADS가 제한 주식단위(RSUs)이며 2025년 10월 31일에 vest됩니다. 각 ADS는 회사의 2,000주 일반주를 나타냅니다.

Akari Therapeutics (AKTX) a divulgué un Form 4 indiquant que son CFO intérimaire a acquis 6 277 Adrs sur le 22 octobre 2025, reporté sous le code A à $0,74 par ADS. À la suite de la transaction, 6 277 ADS sont détenues bénéficiairement avec une propriété directe.

Le dossier précise que ces ADS représentent des unités d’actions restreintes (RSUs) qui viennent à maturité le 31 octobre 2025. Chaque ADS représente 2 000 actions ordinaires de la société.

Akari Therapeutics (AKTX) veröffentlichte Form 4, dass sein Interim-CFO 6.277 American Depositary Shares am 22. Oktober 2025 erworben hat, gemeldet als Code A zu $0,74 pro ADS. Nach der Transaktion sind 6.277 ADS mit direkter Eigentümerschaft vorteilhaft gehalten.

Die Einreichung stellt fest, dass diese ADS Restricted Stock Units (RSUs) sind, die am 31. Oktober 2025 vesten. Jede ADS repräsentiert 2.000 Stammaktien des Unternehmens.

Akari Therapeutics (AKTX) كشفت عن نموذج 4 يبيّن أن مديرها المالي المؤقت اشترى 6,277 سهماً أمريكياً مُصدّراً (ADS) في 22 أكتوبر 2025، مُبلّغ عنها كرمز A بقيمة $0.74 للسهم ADS. بعد الصفقة، أصبحت 6,277 ADS مملوكة بشكل مستفيد بملكية مباشرة.

تشير الإيداع إلى أن هذه هي وحدات أسهم مقيدة (RSUs) التي تكتسب الحقوق في 31 أكتوبر 2025. كل ADS تمثل 2,000 سهماً عاديّاً للشركة.

Akari Therapeutics (AKTX) 公布了一份 Form 4,显示其过渡首席财务官在 2025年10月22日 收购了 6,277 股美国存托股票(ADS),按 $0.74 每 ADS 汇报,代码为 A。交易后,6,277 ADS直接 所有权形式被受益所有。

该备案称这些 ADS 代表的是 受限股票单位(RSUs),将于 2025年10月31日 授予/生效。每个 ADS 代表 2,000 股普通股

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Farag Kameel D.

(Last) (First) (Middle)
C/O AKARI THERAPEUTICS PLC
401 EAST JACKSON STREET, SUITE 3300

(Street)
TAMPA FL 33602

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Akari Therapeutics Plc [ AKTX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Interim CFO
3. Date of Earliest Transaction (Month/Day/Year)
10/22/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
American Depositary Shares representing Ordinary Shares(1) 10/22/2025 A 6,277(2) A $0.74 6,277 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Each American Depositary Share ("ADS") represents 2,000 Ordinary Shares with a par value of $0.0001 per Ordinary Share of the Issuer
2. These ADSs represent restricted stock units ("RSUs"), with each such RSU representing the right to receive 2,000 Ordinary Shares par value $0.0001. The RSUs shall vest on October 31, 2025.
/s/ Abizer Gaslightwala, Attorney-in-Fact 10/24/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Akari Therapeutics Plc

NASDAQ:AKTX

AKTX Rankings

AKTX Latest News

AKTX Latest SEC Filings

AKTX Stock Data

24.10M
24.55M
34.29%
1.73%
0.08%
Biotechnology
Pharmaceutical Preparations
Link
United States
BOSTON